Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed a minor adjustment to its share capital following a repurchase on 26 May 2026.

The company bought back 100,000 H-shares on the Hong Kong Stock Exchange at prices between HKD 3.41 and HKD 3.42, for a volume-weighted average cost of HKD 3.414 per share. The total consideration amounted to HKD 0.34 million. All repurchased shares were retained as treasury stock; none were cancelled.

After the transaction, Weigao Group’s issued share count (excluding treasury shares) declined by 0.0022 % to 4.47 billion, while treasury shares increased to 56.50 million. The overall issued share capital (including treasury shares) remained 4.52 billion.

The repurchase falls under the mandate approved on 27 May 2025, which authorises the company to buy back up to 451.56 million shares—equivalent to 11.04 % of the issued share base on the mandate date. To date, Weigao Group has repurchased a cumulative 49.85 million shares under this authority.

Under Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 June 2026.

The disclosure was signed by Company Secretary Phillis Wong and confirms compliance with all applicable listing and regulatory requirements.